KMT2A

Across TCGA pan-cancer cohorts, KMT2A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KMT2A data layer compared with 27 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher KMT2A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated KMT2A expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where KMT2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.876	0.579	.006	34	view →
HNSC	DFS	Median	IV	0.889	0.407	.042	3	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
GBM	OS	Median	All	0.517	0.300	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

KMT2A–LUAD (OS)

Open the LUAD breakdown →